Leukemia Myeloid

• EMA approval · 2026-07-31
  EMA Authorised: Iclusig (ponatinib) — Incyte Biosciences Distribution B.V.

  The EMA authorizes Iclusig (ponatinib) for leukemia indications under accelerated assessment.

• CLINICAL_TRIALS trial_result · 2018-08-13
  Clinical Trial Update: Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies [Phase 2]

  Phase 2 clinical trial update evaluating reduced toxicity conditioning before unrelated cord blood cell transplantation in high-risk myeloid…